The Discounted Cash Flow (DCF) valuation of Talis Biomedical Corp (TLIS) is (1.37) USD. With the latest stock price at 4.38 USD, the upside of Talis Biomedical Corp based on DCF is -131.3%.
Based on the latest price of 4.38 USD and our DCF valuation, Talis Biomedical Corp (TLIS) is a sell. selling TLIS stocks now will result in a potential gain of 131.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.1% - 6.6% | 5.9% |
| Long-term Growth Rate | 3.0% - 4.9% | 3.9% |
| Fair Price | (41.13) - 1.40 | (1.37) |
| Upside | -1039.0% - -68.1% | -131.3% |